Skip to main content

Why testing for HRR+ at progression to metastatic disease matters

~20% of patients with mCRPC harbour one or more HRR mutations(1,2)

Those diagnosed with metastatic disease have a 5-year relative survival rate of only 30%3

  • Risk of death was significantly higher in patients with BRCA2 alterations vs noncarriers (HR, 2.21; p<0.01)4

  • Cause-specific survival (CSS) for BRCA2 carriers was approximately halved vs noncarriers (17.4 vs 33.2 months; p=0.027: HR, 2.10, 95% CI, 1.07 to 4.10)5

  • >90% of patients with mCRPC have bone metastases, which are commonly associated with skeletal-related complications that can increase mortality and disability and negatively affect quality of life6,7

The understanding around genetic mutations in prostate cancer and their implications on long-term patient outcomes is still evolving. Identifying HRR mutations can help reveal that the patient’s prostate cancer is more aggressive vs that of those without HRR+ disease.1

mCRPC with HRR mutations has been associated with:

  • Poor prognosis8
  • A higher recurrence rate1,8
  • More aggressive disease8

Patients with BRCA2 mutations have a 20-fold risk of death related to prostate cancer.1

Identify patients at higher risk early

Test at diagnosis of metastatic disease to better understand the prognosis and determine the next steps1

BRCA1: Breast cancer gene 1

BRCA2: Breast cancer gene 2

HRR: Homologous recombination repair

mCRPC: Metastatic castration-resistant prostate cancer

REFERENCES: 1. Teyssonneau D, Margot H, Cabart M, et al. J Hematol Oncol 2021;14(51):1–19. ↵  2. Robinson&nbsp;D, Van&nbsp;Allen&nbsp;EM, Wu&nbsp;Y, et al. Cell 2015;161(5):1215–1228.↵  3. American Cancer Society. Survival Rates for Prostate Cancer. Available: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html. ↵  4. Cui M, Gao X, Gu X, et al. Oncotarget 2017;8(25):40222–40232.↵  5. Castro E, Romero-Laorden N, del Pozo A, et al. J Clin Oncol 2019;37(6):490–503. ↵  6. Den RB, George D, Pieczonka C, et al. Am J Clin Oncol 2019;42(4):399–406. ↵  7. Bazarbashi S, Su W-P, Wong SW, et al. Oncol Ther 2021;9(2):311–327. ↵  8. Scott RJ, Mehta A, Macedo GS, et al. Oncotarget 2021;12(16):1600–1614.↵